IL226504B - Increasing drug bioavailability in naltrexone therapy - Google Patents

Increasing drug bioavailability in naltrexone therapy

Info

Publication number
IL226504B
IL226504B IL226504A IL22650413A IL226504B IL 226504 B IL226504 B IL 226504B IL 226504 A IL226504 A IL 226504A IL 22650413 A IL22650413 A IL 22650413A IL 226504 B IL226504 B IL 226504B
Authority
IL
Israel
Prior art keywords
naltrexone
bioavailability
drug
increasing
treatment
Prior art date
Application number
IL226504A
Other languages
English (en)
Hebrew (he)
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL226504(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of IL226504B publication Critical patent/IL226504B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
IL226504A 2010-12-03 2013-05-23 Increasing drug bioavailability in naltrexone therapy IL226504B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03
PCT/US2011/063177 WO2012075459A1 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy

Publications (1)

Publication Number Publication Date
IL226504B true IL226504B (en) 2021-01-31

Family

ID=46172304

Family Applications (3)

Application Number Title Priority Date Filing Date
IL226504A IL226504B (en) 2010-12-03 2013-05-23 Increasing drug bioavailability in naltrexone therapy
IL270841A IL270841A (en) 2010-12-03 2019-11-21 Increasing the bioavailability of a drug in treatment with naltrexone
IL279626A IL279626A (en) 2010-12-03 2020-12-21 Increasing the bioavailability of a drug in treatment with naltrexone

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL270841A IL270841A (en) 2010-12-03 2019-11-21 Increasing the bioavailability of a drug in treatment with naltrexone
IL279626A IL279626A (en) 2010-12-03 2020-12-21 Increasing the bioavailability of a drug in treatment with naltrexone

Country Status (27)

Country Link
US (1) US20130245056A1 (OSRAM)
EP (4) EP3222280B1 (OSRAM)
JP (5) JP6008866B2 (OSRAM)
KR (5) KR102391511B1 (OSRAM)
CN (1) CN103313711A (OSRAM)
AR (2) AR093182A1 (OSRAM)
AU (2) AU2011336304B2 (OSRAM)
BR (1) BR112013013390A2 (OSRAM)
CA (2) CA2819262C (OSRAM)
CL (1) CL2013001564A1 (OSRAM)
CY (2) CY1118968T1 (OSRAM)
DK (3) DK3884947T3 (OSRAM)
ES (2) ES2866879T3 (OSRAM)
FI (1) FI3884947T3 (OSRAM)
HR (3) HRP20170734T1 (OSRAM)
HU (3) HUE065852T2 (OSRAM)
IL (3) IL226504B (OSRAM)
LT (3) LT3222280T (OSRAM)
MX (2) MX384662B (OSRAM)
PL (3) PL3884947T3 (OSRAM)
PT (3) PT3222280T (OSRAM)
RS (3) RS56014B1 (OSRAM)
RU (1) RU2640561C2 (OSRAM)
SI (3) SI3222280T1 (OSRAM)
SM (3) SMT202100227T1 (OSRAM)
TW (1) TWI618536B (OSRAM)
WO (1) WO2012075459A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
KR20120124423A (ko) 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
PL3884947T3 (pl) * 2010-12-03 2024-05-06 Nalpropion Pharmaceuticals Llc Wzrost biodostępności leku w terapii naltreksonem
RS67076B1 (sr) 2012-06-06 2025-08-29 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
WO2016125109A1 (en) * 2015-02-07 2016-08-11 Intas Pharmaceuticals Ltd. Pharmaceutical composition for the treatment of obesity
CN111050801B (zh) * 2017-03-28 2023-03-28 Ldn制药有限公司 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
KR20080042092A (ko) 2005-07-27 2008-05-14 오렉시젠 세러퓨틱스 인크. 체중감량 조성물
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
EP1954316A1 (en) 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
ES2636657T3 (es) * 2006-06-19 2017-10-06 Alpharma Pharmaceuticals Llc Composición farmacéutica
KR101264789B1 (ko) * 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
CA2693992C (en) * 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
CN101573103A (zh) 2006-11-09 2009-11-04 奥雷西根治疗公司 用于施用重量减轻药物的单位剂量包装和方法
AR063959A1 (es) * 2006-11-09 2009-03-04 Orexigen Therapeutics Inc Formulaciones farmaceuticas en capas
DK3461503T3 (da) * 2007-04-11 2022-02-14 Biomarin Pharm Inc Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
PL3884947T3 (pl) * 2010-12-03 2024-05-06 Nalpropion Pharmaceuticals Llc Wzrost biodostępności leku w terapii naltreksonem

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GREENWAY FL. ET. AL., GREENWAY FL. ET. AL., LANCET. 2010 AUG 21;376(9741):595-605., 21 August 2010 (2010-08-21) *

Also Published As

Publication number Publication date
MX356801B (es) 2018-06-13
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26
JP2024071605A (ja) 2024-05-24
AU2011336304B2 (en) 2017-03-30
RU2017144631A3 (OSRAM) 2021-04-13
CY1124331T1 (el) 2022-07-22
CN103313711A (zh) 2013-09-18
JP2019056004A (ja) 2019-04-11
EP3222280A1 (en) 2017-09-27
ES2866879T3 (es) 2021-10-20
HUE065852T2 (hu) 2024-06-28
AU2011336304A1 (en) 2013-07-11
RU2013127423A (ru) 2015-01-10
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
SMT201700232T1 (it) 2017-07-18
KR102105857B1 (ko) 2020-05-04
LT3222280T (lt) 2021-05-10
SMT202400038T1 (it) 2024-03-13
PT3222280T (pt) 2021-04-22
JP2013544290A (ja) 2013-12-12
HRP20170734T1 (hr) 2017-08-11
SMT202100227T1 (it) 2021-07-12
JP2016210809A (ja) 2016-12-15
IL270841A (en) 2020-01-30
CY1118968T1 (el) 2018-01-10
HUE053831T2 (hu) 2021-07-28
CL2013001564A1 (es) 2014-05-02
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
EP2646031A4 (en) 2014-04-23
RS62149B1 (sr) 2021-08-31
JP2022060331A (ja) 2022-04-14
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
US20130245056A1 (en) 2013-09-19
CA3239386A1 (en) 2012-06-07
HUE034393T2 (en) 2018-02-28
KR101984500B1 (ko) 2019-05-31
EP4349369B1 (en) 2025-09-17
KR20200044158A (ko) 2020-04-28
IL279626A (en) 2021-03-01
EP4349369A2 (en) 2024-04-10
EP3884947B1 (en) 2023-11-15
KR20210063473A (ko) 2021-06-01
PT2646031T (pt) 2017-05-25
KR20190058702A (ko) 2019-05-29
EP4349369A3 (en) 2024-05-15
KR20180069089A (ko) 2018-06-22
JP7025319B2 (ja) 2022-02-24
CA2819262C (en) 2024-05-28
JP6008866B2 (ja) 2016-10-19
MX2013006071A (es) 2013-10-01
HRP20240115T1 (hr) 2024-06-07
KR20140035320A (ko) 2014-03-21
PL3222280T3 (pl) 2021-11-29
LT2646031T (lt) 2017-06-26
RU2017144631A (ru) 2019-02-18
ES2625527T3 (es) 2017-07-19
MX384662B (es) 2025-03-14
RS65198B1 (sr) 2024-03-29
EP2646031B9 (en) 2018-01-10
AR093182A1 (es) 2015-05-27
HRP20210618T1 (hr) 2021-09-17
DK3222280T3 (da) 2021-04-19
AU2017204309A1 (en) 2017-07-13
EP2646031A1 (en) 2013-10-09
EP3222280B1 (en) 2021-01-20
EP3884947A1 (en) 2021-09-29
PL3884947T3 (pl) 2024-05-06
SI3884947T1 (sl) 2024-06-28
SI2646031T1 (sl) 2017-07-31
WO2012075459A1 (en) 2012-06-07
JP6456890B2 (ja) 2019-01-23
FI3884947T3 (fi) 2024-01-30
AR124500A2 (es) 2023-04-05
SI3222280T1 (sl) 2021-11-30
ES2625527T9 (es) 2018-09-25
RU2640561C2 (ru) 2018-01-09
DK2646031T3 (en) 2017-05-22
TW201304780A (zh) 2013-02-01
PT3884947T (pt) 2024-02-16
TWI618536B (zh) 2018-03-21
LT3884947T (lt) 2024-03-12

Similar Documents

Publication Publication Date Title
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
CY2018029I2 (el) Αντι-ιικη θεραπεια
IL226504B (en) Increasing drug bioavailability in naltrexone therapy
IL226245A0 (en) History
IL245328A0 (en) Pharmaceutical composition
EP2748685A4 (en) PORTABLE MEDICINAL DISPENSER
EP2753233A4 (en) MEDICAL DEVICES WITH PROXIMITY DETECTION
HUE037108T2 (hu) Adagkapszula azonosítóval
ATE526024T1 (de) Fluvoxamin vermeidende pirfenidontheraphy
DK2652652T3 (da) Medikmentadministration
SI2582366T1 (sl) Farmacevtska kombinacija za zdravljenje bolečine
FI20105639A7 (fi) Mikroselluloosan valmistus
DK2437736T3 (da) Lægemiddelindgivelsessystemer
GB201017597D0 (en) Drug detection
BR112013008074A2 (pt) combinações farmacêuticas
EP2883547A4 (en) MEDICINE
HUE049344T2 (hu) Gyermekgyógyászati készítmény
BR112013000298A2 (pt) tablete
EP2564818A4 (en) MEDICAL STENT
DK2555819T3 (da) Lægemiddelafgivelsesindretning
ES1075346Y (es) Cateter integrado anti-retorno
FI20100366A0 (fi) Järjestelmä lääkityksen noudattamiseksi
IT1401468B1 (it) Contenitore per farmaci
FR2990112B1 (fr) Support d'assise
DK2670458T3 (da) Lægemiddelindgivelsesanordning

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed